Do you suffer from ulcers or gastritis? A recent clinical trial has discovered Vonoprazan is an effective treatment for people with H. pylori infections, especially clarithromycin-resistant strains. And, especially important, it is an alternate treatment to antibiotics.
Helicobacter pylori (H.pylori) is a bacterium that lives in the stomach and causes various digestive problems such as ulcers and gastritis. Standard treatment for this infection includes a triple therapy consisting of two antibiotics and a proton pump inhibitor.
However, resistance to these antibiotics is on the rise, making it difficult to treat the infection effectively. Therefore, researchers have been searching for more effective treatments. One such treatment is vonoprazan, a potassium-competitive acid blocker that has shown promising results in clinical trials.
A recent clinical trial evaluated the efficacy of vonoprazan-based dual therapy versus standard triple therapy in the United States and Europe. The trial included 1,046 treatment-naïve adults with H pylori infection who were randomized to receive either vonoprazan dual therapy or standard triple therapy for 14 days.
The primary outcome of the study was similar eradication rates in patients with non-resistant strains. The secondary outcomes included superior eradication rates in all patients with resistant strains.
The study found that treatments using vonoprazan were better than treatments using a proton pump inhibitor, especially for infections that were resistant to clarithromycin.
For patients with non-resistant infections, the vonoprazan treatments had an eradication rate of about 79% to 85%, which was similar to the standard treatment with lansoprazole.
However, for patients with clarithromycin-resistant infections, the vonoprazan treatments had much higher eradication rates (about 66% to 70%) compared to the standard treatment (about 32%).
The study also found that the overall frequency of adverse events was similar between vonoprazan and lansoprazole regimens, with no significant differences observed.
The results of this clinical trial suggest that vonoprazan-based regimens are more effective than standard triple therapy in treating H pylori infections, especially in patients with clarithromycin-resistant strains.
Vonoprazan dual therapy and triple therapy have also been shown to be similar in efficacy to the standard triple therapy in patients with non-resistant strains. These findings are significant as they provide a potential alternative treatment option for patients with H pylori infections, particularly those who are resistant to the standard treatment.